메뉴 건너뛰기




Volumn 32, Issue 30, 2014, Pages 3391-3399

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study

(21)  Smith, Matthew R a   Sweeney, Christopher J b   Corn, Paul G c   Rathkopf, Dana E d   Smith, David C e   Hussain, Maha e   George, Daniel J f   Higano, Celestia S h   Harzstark, Andrea L i   Sartor, A Oliver k   Vogelzang, Nicholas J l   Gordon, Michael S m   De Bono, Johann S o   Haas, Naomi B n   Logothetis, Christopher J c   Elfiky, Aymen b   Scheffold, Christian j   Laird, A Douglas j   Schimmoller, Frauke j   Basch, Ethan M g   more..


Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CABOZANTINIB; HEMOGLOBIN; NARCOTIC ANALGESIC AGENT; PROSTATE SPECIFIC ANTIGEN; ANILIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE;

EID: 84905170852     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.5954     Document Type: Article
Times cited : (111)

References (11)
  • 1
    • 83355166909 scopus 로고    scopus 로고
    • Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
    • Yakes FM, Chen J, Tan J, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10:2298-2308, 2011
    • (2011) Mol Cancer Ther , vol.10 , pp. 2298-2308
    • Yakes, F.M.1    Chen, J.2    Tan, J.3
  • 2
    • 84875469411 scopus 로고    scopus 로고
    • Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone
    • Schimmoller F, Zayzafoon M, Chung LWK, et al: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone. Mol Cancer Ther 10:233, 2011 (suppl 1; abstr A233)
    • (2011) Mol Cancer Ther , vol.10 , pp. 233
    • Schimmoller, F.1    Zayzafoon, M.2    Chung, L.W.K.3
  • 3
    • 84886383394 scopus 로고    scopus 로고
    • Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling
    • Nguyen HM, Ruppender N, Zhang X, et al: Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 8:e78881, 2013
    • (2013) PLoS One , vol.8 , pp. e78881
    • Nguyen, H.M.1    Ruppender, N.2    Zhang, X.3
  • 4
    • 84898853470 scopus 로고    scopus 로고
    • Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib
    • Graham TJ, Box G, Tunariu N, et al: Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst 106:dju033, 2014
    • (2014) J Natl Cancer Inst , vol.106 , pp. dju033
    • Graham, T.J.1    Box, G.2    Tunariu, N.3
  • 5
    • 84874787799 scopus 로고    scopus 로고
    • Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial
    • Smith DC, Smith MR, Sweeney C, et al: Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol 31:412-419, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 412-419
    • Smith, D.C.1    Smith, M.R.2    Sweeney, C.3
  • 6
    • 84878961883 scopus 로고    scopus 로고
    • A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases
    • Lee RJ, Saylor PJ, Michaelson MD, et al: A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 19:3088-3094, 2013
    • (2013) Clin Cancer Res , vol.19 , pp. 3088-3094
    • Lee, R.J.1    Saylor, P.J.2    Michaelson, M.D.3
  • 7
    • 84863230043 scopus 로고    scopus 로고
    • Computer-aided quantitative bone scan assessment of prostate cancer treatment response
    • Brown MS, Chu GH, Kim HJ, et al: Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nucl Med Commun 33:384-394, 2012
    • (2012) Nucl Med Commun , vol.33 , pp. 384-394
    • Brown, M.S.1    Chu, G.H.2    Kim, H.J.3
  • 8
    • 41949104346 scopus 로고    scopus 로고
    • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
    • Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 1148-1159
    • Scher, H.I.1    Halabi, S.2    Tannock, I.3
  • 9
    • 79959269553 scopus 로고    scopus 로고
    • Circulating tumor cells as biomarkers in prostate cancer
    • Danila DC, Fleisher M, Scher HI: Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17:3903-3912, 2011
    • (2011) Clin Cancer Res , vol.17 , pp. 3903-3912
    • Danila, D.C.1    Fleisher, M.2    Scher, H.I.3
  • 10
    • 0034748159 scopus 로고    scopus 로고
    • Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale
    • Farrar JT, Young JP Jr, LaMoreaux L, et al: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149-158, 2001
    • (2001) Pain , vol.94 , pp. 149-158
    • Farrar, J.T.1    Young, J.P.2    LaMoreaux, L.3
  • 11
    • 84921491789 scopus 로고    scopus 로고
    • Effects of cabozantinib on pain and narcotic use in patients with castration-resistance prostate cancer: Results from a phase 2 nonrandomized expansion cohort
    • epub ahead of print on February 20, 2014
    • Basch EM, Autio KA, Smith MR, et al: Effects of cabozantinib on pain and narcotic use in patients with castration-resistance prostate cancer: Results from a phase 2 nonrandomized expansion cohort. Eur Urol [epub ahead of print on February 20, 2014]
    • Eur Urol
    • Basch, E.M.1    Autio, K.A.2    Smith, M.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.